Suchergebnisse - "Kivitz, Alan J"

PubPharm (173)

1

Efficacy and Safety of Secukinumab in US Patients with Psoriatic Arthritis : A Subgroup Analysis of the Phase 3 FUTURE Studies

enthalten in: Rheumatology and therapy | 2024

von Kivitz, A. | Kremer, J. | Legerton, C. | +2

2

The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout

enthalten in: Rheumatology (Oxford, England) | 2024

von Baraf, H. | Khanna, P. | Kivitz, A. | +8

3

Long-term safety and efficacy of sarilumab with or without background csDMARDs in rheumatoid arthritis

enthalten in: Rheumatology (Oxford, England) | 2023

von Burmester, G. | Strand, V. | Kivitz, A. | +5

4

Safety and efficacy of filgotinib for Japanese patients with RA and inadequate response to MTX : FINCH 1 52-week results and FINCH 4 48-week results

enthalten in: Modern rheumatology | 2023

von Tanaka, Y. | Matsubara, T. | Atsumi, T. | +18

5

Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX : A Post Hoc Analysis of the FINCH 1 Study

enthalten in: Rheumatology and therapy | 2023

von Combe, B. | Tanaka, Y. | Buch, M. | +11

ErratumIn: Rheumatol Ther. 2023 Jan 4;:. - PMID 36598735

6

Correction : Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

enthalten in: Rheumatology and therapy | 2023

von Combe, B. | Tanaka, Y. | Buch, M. | +11

ErratumFor: Rheumatol Ther. 2023 Feb;10(1):53-70. - PMID 36209441

7

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

enthalten in: Rheumatology and therapy | 2023

von Combe, B. | Tanaka, Y. | Buch, M. | +11

8

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

enthalten in: Rheumatology and therapy | 2023

von Combe, B. | Tanaka, Y. | Buch, M. | +11

9

Correction: Efficacy and Safety of Filgotinib in Patients with High Risk of Poor Prognosis Who Showed Inadequate Response to MTX: A Post Hoc Analysis of the FINCH 1 Study

enthalten in: Rheumatology and therapy | 2023

von Combe, B. | Tanaka, Y. | Buch, M. | +11

10

Safety and Efficacy of Bimekizumab in Patients With Active Ankylosing Spondylitis : Three-Year Results From a Phase IIb Randomized Controlled Trial and Its Open-Label Extension Study

enthalten in: Arthritis & rheumatology (Hoboken, N.J.) | 2022

von Baraliakos, X. | Deodhar, A. | Dougados, M. | +12

CommentIn: Nat Rev Rheumatol. 2022 Sep;18(9):494. - PMID 35922551

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[18]